EQUITY RESEARCH MEMO
SciGenom
Generated 5/9/2026
Executive Summary
Conviction (model self-assessment)65/100
SciGenom is a leading genomics service provider founded in 2009, with state-of-the-art laboratories in Cochin, Chennai, Hyderabad, and a presence in Fremont, CA. The company offers end-to-end NGS, Sanger sequencing, bioinformatics, and real-time PCR services, leveraging Illumina and ABI platforms. Certified under NABL, ISO, and GLP, SciGenom serves research and diagnostics markets across India, Asia, and the USA. As a private entity, it is well-positioned to benefit from the growing demand for genomic services, particularly in emerging markets where cost-effective solutions are critical. The company’s DSIR-recognized R&D and proprietary SAIF database strengthen its competitive edge.
Upcoming Catalysts (preview)
- Q3 2026Expansion of clinical diagnostic services in India70% success
- Q4 2026Strategic partnership with a global pharma company for oncology genomics50% success
- Q1 2027Launch of new liquid biopsy NGS panel60% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)